Yearly Archives : 2015

Terms and Condition of Use

On November 24, 2015, In Uncategorized,

Black Swan Analysis Limited and its affiliates provide their services to you subject to the following conditions. If you visit or shop at Epiomic.com, you accept these conditions. Please read them carefully. We reserve the right from time to time to make changes to these Terms and Conditions at our…

Black Swan Analysis short-listed for the “Management Team of the Year” category at this year’s Thames Valley Business Awards

On October 29, 2015, In News, Tags

Black Swan Analysis has just been short-listed for the “The Management Team of the Year Award” sponsored by NatWest and open to outstanding management teams in the Thames Valley. We are joined on the short-list by 5 other companies with management teams that display a truly motivational, enlightened, innovative, and…

Black Swan Analysis short-listed for the “Micro Business of the Year” category at this year’s National Growing Business Awards

On September 30, 2015, In News, Tags ,

Black Swan Analysis has been shortlisted for the Micro Business of the Year category, for this year’s Growing Business Awards, in association with Lloyds Bank, supported by Real Business and the CBI. There were a large number of high calibre nominations this year for the category so we are pleased to have made…

A look into…Sickle Cell Disease

Although Sickle Cell Disease (SCD) is the most frequent haemoglobinopathy worldwide, it remains a rare blood disorder in most western countries. Globally, an estimated 5% of the world’s population are carriers of rare haemoglobinopathies, with over 300,000 sufferers of SCD worldwide. SCD is usually endemic in individuals whose ancestors originate…

Robust Data Forecasts in the changing healthcare environment

On August 24, 2015, Tags
What’s the issue? The healthcare environment today is not what it used to be. Over the past several decades many pharmaceutical companies have primarily focused on main stream diseases affecting larger populations with unmet clinical needs and limited treatment options. Pharma companies set their sights on discovering blockbuster drugs to address a medical problem for…